Dr. Scott Dobson, M.D.
Pediatrics (Pediatrics Physician)
211 Batesville Rd
Simpsonville, SC 29681
Who else practices at this address →
Greenville County is a federal mental health shortage area. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
SC license 24580
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $1,502 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,336 |
|---|---|
| Novo Nordisk Inc | $94.18 |
| Amgen Inc. | $23.58 |
| Cranial Technologies, Inc | $20.31 |
| Tris Pharma Inc | $14.61 |
| Novartis Pharmaceuticals Corporation | $13.51 |
| Travel and Lodging | $978 |
|---|---|
| Food and Beverage | $524 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging VACCINE · travel to Orlando, FL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $648 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging VACCINE · travel to Orlando, FL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $291 |
| Merck Sharp & Dohme LLC Dec 17, 2025 | Travel and Lodging VACCINE · travel to Orlando, FL Company’s descriptionProvided as part of a clinical research engagement. | $38.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 7 companies. The companies reported $453,750 in research payments for these studies, mostly to the institutions running them.
- A phase 3A, observer-blind, randomized, controlled study to demonstrat
GlaxoSmithKline, LLC. - Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06397768 - A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Novavax Inc - Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06736041 - A phase 2, randomized, double-blind, multi-dose, dose finding study to
GlaxoSmithKline, LLC. - A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06705140 - A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company · Active, not recruiting · NCT03432286 - A phase ii, single-blind, randomized, controlled study to evaluate the
GlaxoSmithKline, LLC. - A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
Merck Sharp & Dohme LLC - A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.